BioHiTech Global Reports Record Results With Third Quarter Revenue Up Over 500% From Year-Ago Period
BioHiTech Global (NASDAQ: BHTG) reported a remarkable Q3 2021, with revenues reaching $4.5 million, marking a 509% increase year-over-year and a 31% increase from the previous quarter. This growth is primarily driven by equipment sales to Carnival Cruise Lines. The company also noted an improvement in its operating loss, which reduced to ($1.1 million) from ($3.9 million) a year prior. Gross margins increased to 23% compared to 14% in Q2. The company continues to explore new markets, including supermarkets and higher education institutions.
- Total revenues increased to $4.5 million, up 509% year-over-year and 31% quarter-over-quarter.
- Operating loss improved to ($1.1 million) from ($3.9 million) in the same quarter last year.
- Gross margins increased to 23% from 14% in the prior quarter, reflecting operational efficiency.
- Selling, General and Administrative (SG&A) expenses declined to $1.7 million, showing cost optimization.
- Consolidated net loss was $1.8 million, including a net loss attributable to parent of $1.2 million.
CHESTNUT RIDGE, N.Y., Nov. 18, 2021 /PRNewswire/ -- BioHiTech Global, Inc. ("BioHiTech" or the "Company") (NASDAQ: BHTG), a sustainable technology and services company, today announces financial results for its fiscal third quarter ending September 30, 2021.
Q3 2021 Financial Highlights
- The Company continued its revenue growth in the quarter ended September 30, 2021, with total revenues of
$4.5 million , up509% over the year-ago quarter and31% over the prior quarter. - Third quarter Digester and Corporate line of business revenues increased by approximately
431% over the year-ago period and28% over the prior quarter, driven by Carnival Cruise Lines equipment sales. - Operating loss improves to (
$1.1) million versus a loss of ($3.9) million in the year-ago period and ($2.0) million in the prior quarter.
Corporate Highlights Q3 2021
- BioHiTech continues growth in Cruise industry with strong Carnival Corp. sales
- BioHiTech expands market presence in Higher Education Institutions with additional Digester Sales and student research opportunities
- BioHiTech engages pilot efforts to explore Digester use in Supermarkets
Tony Fuller, BioHiTech's CEO, commented: "We are pleased with our third quarter performance which represents the fourth consecutive quarter of record revenue for BioHiTech, with revenues rising
"Our success in the third quarter is a true testament to the dedication and perseverance of our amazing team who have surpassed our goals through a shifting macroeconomic landscape. We continue to accomplish strong growth in our Maritime/Cruise vertical while fostering an expansion in Higher Education, Retail, and other verticals. Moreover, we achieved strong performance in our Martinsburg Plant, which is operating with stronger, more efficient output given the resolution of the issues that hampered sales in recent quarters.
"Our efforts in the Higher Education vertical have driven growth through additional digester orders at prominent universities across the East Coast as they seek to accomplish sweeping sustainability goals including increasing landfill diversion and reducing their carbon footprint. We have also worked with these institutions to provide groundbreaking research and educational opportunities for students to gain a unique perspective on the impact of our solutions on myriad climate impacting factors, waste management and new technologies to achieve sustainability goals.
"Our team is also expanding pilot efforts exploring the benefits that large supermarket chains may gain from employing our Digesters, enabling efficiencies, and mitigating waste at its source throughout their operations.
"We are also currently evaluating numerous complementary strategic alliances or acquisition candidates that are part of our ongoing efforts to identify potentially accretive opportunities. We anticipate our growth will continue to come from organic sales of our technology solutions, sales of Solid Recovered Fuel, as well as potential acquisitions that support our mission as a company and a responsible corporate citizen," concluded Mr. Fuller.
Financial Results for the Quarter ended September 30, 2021
The Company continued its revenue growth in the quarter ended September 30, 2021, with total revenues of
The overall contribution (revenues, less direct costs) increased to
Selling, general and administrative expenses (SG&A) declined to
The loss from operations improved to
For the three months ended September 30, 2021, the Company incurred a consolidated loss from operations of
At September 30, 2021, restricted cash was
Conference Call to be held Thursday, November 18, 2021, at 4:30 PM ET
Mr. Tony Fuller, Chief Executive Officer of BioHiTech, will host a conference call on Thursday, November 18, 2021, at 4:30 p.m. ET to discuss the Company's financial results for the third quarter ended September 30, 2021. Also joining Mr. Fuller on the call from management will be Brian Essman, Chief Financial Officer. Following management's formal remarks, there will be a live question-and-answer session.
Participants are asked to pre-register for the call via the following link:
https://dpregister.com/sreg/10161284/eed72a81e4
Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-866-652-5200 (domestic) or 1-412-317-6060 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioHiTech Global call.
The conference call will be available through a live webcast found at:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=Utji6Ctk
It will also be broadcast live through the Company's website with the following link:
http://investors.biohitechglobal.com/events-and-webcasts
A webcast replay of the call will be available approximately one hour after the end of the call through February 18, 2022. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10159374. A telephonic replay of the call will be available through November 29, 2021.
About BioHiTech Global
BioHiTech Global, Inc. (NASDAQ: BHTG), is a technology services company focused on providing cost-effective solutions that improve environmental outcomes. Our technologies for waste management include the processing of municipal solid waste into a valuable renewable fuel, biological disposal of food waste on-site, and proprietary real-time data analytics tools to reduce food waste generation. When used individually or in combination, our solutions lower the carbon footprint associated with waste transportation and can reduce or virtually eliminate landfill usage. Our unique solutions enable businesses of all types as well as educational and governmental facilities to solve everyday problems in a smarter and more cost-effective way while reducing their impact on the environment. For more information, please visit www.biohitech.com.
Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, including statements about the estimated contract value, additional purchase orders or deliveries, and the ability of the Company's products to improve environmental outcomes and achieve corporate sustainability goals, are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of BioHiTech Global, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. BioHiTech Global, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"). There may be other factors not mentioned above or included in the BioHiTech's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. BioHiTech Global, Inc. assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Company Contact:
BioHiTech Global, Inc.
Lisa Giovannielli
VP, Corporate Communications
O: 888.876.9300
E: lgiovannielli@biohitech.com
Investors:
ir@biohitech.com
Financial Tables Follow
BioHiTech Global, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | ||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||
September 30, | September 30, | |||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||
Revenue | ||||||||||||
Equipment sales | $ | 3,152,639 | $ | 293,876 | $ | 8,050,145 | $ | 616,992 | ||||
Rental, service and maintenance | 785,576 | 423,996 | 1,654,232 | 1,251,122 | ||||||||
HEBioT | 585,102 | 625 | 1,314,204 | 1,383,656 | ||||||||
Management advisory and other fees (related party) | — | 24,380 | — | 124,380 | ||||||||
Total revenue | 4,523,317 | 742,877 | 11,018,581 | 3,376,150 | ||||||||
Operating expenses | ||||||||||||
Equipment sales | 2,112,407 | 171,002 | 5,154,747 | 317,406 | ||||||||
Rental, service and maintenance | 455,436 | 139,665 | 1,008,608 | 552,195 | ||||||||
HEBioT processing | 898,094 | 945,810 | 2,454,862 | 2,778,514 | ||||||||
Selling, general and administrative | 1,699,343 | 1,924,293 | 5,357,697 | 5,740,158 | ||||||||
Impairment expense | — | 917,420 | — | 917,420 | ||||||||
Depreciation and amortization | 505,353 | 562,143 | 1,508,284 | 1,747,109 | ||||||||
Total operating expenses | 5,670,633 | 4,660,333 | 15,484,198 | 12,052,802 | ||||||||
Loss from operations | (1,147,316) | (3,917,456) | (4,465,617) | (8,676,652) | ||||||||
Other expenses, net | ||||||||||||
Interest (income) | (159) | (108) | (469) | (17,730) | ||||||||
Interest expense | 1,042,253 | 1,023,165 | 3,101,669 | 3,060,775 | ||||||||
(Gain) on sales of fixed assets | (8,957) | — | (8,957) | — | ||||||||
PPP Loan forgiveness | (421,300) | — | (421,300) | — | ||||||||
Loss from unconsolidated entity | 10,982 | — | 43,731 | — | ||||||||
Total other expenses, net | 622,819 | 1,023,057 | 2,714,674 | 3,043,045 | ||||||||
Net loss | (1,770,135) | (4,940,513) | (7,180,291) | (11,719,697) | ||||||||
Net loss attributable to non-controlling interests | (583,261) | (1,647,782) | (1,979,000) | (3,190,788) | ||||||||
Net loss attributable to Parent | (1,186,874) | (3,292,731) | (5,201,291) | (8,528,909) | ||||||||
Other comprehensive income | ||||||||||||
Foreign currency translation adjustment | 32,810 | 71,067 | 16,766 | 40,931 | ||||||||
Comprehensive loss | $ | (1,154,064) | $ | (3,221,664) | $ | (5,184,525) | $ | (8,487,978) | ||||
Net loss attributable to Parent | $ | (1,186,874) | $ | (3,292,731) | $ | (5,201,291) | $ | (8,528,909) | ||||
Less – preferred stock dividends | (175,169) | (205,115) | (533,193) | (587,428) | ||||||||
Deemed dividend on down round features | (622,482) | (21,738) | (622,482) | (21,738) | ||||||||
Net loss – common shareholders | (1,984,525) | (3,519,584) | (6,356,966) | (9,138,075) | ||||||||
Net loss per common share - basic and diluted | $ | (0.07) | $ | (0.16) | $ | (0.24) | $ | (0.49) | ||||
Weighted average number of common shares outstanding - | 28,478,706 | 22,044,540 | 27,034,898 | 18,787,566 | ||||||||
BioHiTech Global, Inc. and Subsidiaries Condensed Consolidated Balance Sheets | ||||||
September 30, | ||||||
2021 | December 31, | |||||
(Unaudited) | 2020 | |||||
(Revised) | ||||||
Assets | ||||||
Current Assets | ||||||
Cash | $ | 622,088 | $ | 2,403,859 | ||
Restricted cash | 3,764,521 | 1,884,691 | ||||
Accounts receivable, net of allowance for doubtful accounts of | 1,861,455 | 1,574,047 | ||||
Inventory | 1,007,537 | 695,110 | ||||
Prepaid expenses and other current assets | 210,544 | 184,274 | ||||
Total Current Assets | 7,466,145 | 6,741,981 | ||||
Restricted cash | 2,603,506 | 2,607,945 | ||||
Equipment on operating leases, net | 1,037,006 | 1,311,755 | ||||
HEBioT facility, equipment, fixtures and vehicles, net | 35,044,593 | 35,946,225 | ||||
License and capitalized MBT facility development costs | 8,007,484 | 8,072,471 | ||||
Other assets | 1,887,988 | 2,006,048 | ||||
Total Assets | $ | 56,046,722 | $ | 56,686,425 | ||
Liabilities and Stockholders' Equity | ||||||
Current Liabilities | ||||||
Accounts payable | $ | 3,711,475 | $ | 2,492,606 | ||
Accrued expenses and liabilities | 1,477,032 | 2,515,724 | ||||
Accrued interest payable | 758,725 | 1,279,018 | ||||
Customer deposits | 559,106 | 1,802,725 | ||||
Current portion of notes, bonds, debts and borrowings | 10,821,272 | 10,120,457 | ||||
Deferred revenue | 298,752 | 138,961 | ||||
Total Current Liabilities | 17,626,362 | 18,349,491 | ||||
Non-current portion of notes, bonds, debts and borrowings | 28,832,835 | 29,645,227 | ||||
Accrued interest (related party) | 1,982,423 | 1,807,857 | ||||
Non-current lease liabilities | 1,137,806 | 1,216,861 | ||||
Liabilities to non-controlling interests to be settled in subsidiary membership units | — | 1,585,812 | ||||
Total Liabilities | 49,579,426 | 52,605,248 | ||||
Series A redeemable convertible preferred stock, 333,401 shares designated and issued, and 95,312 and | 476,560 | 626,553 | ||||
Commitments and Contingencies | ||||||
Stockholders' Equity | ||||||
Preferred stock, | 5,057,942 | 6,621,576 | ||||
Common stock, | 2,916 | 2,334 | ||||
Additional paid in capital | 75,099,785 | 64,371,007 | ||||
Accumulated deficit | (74,790,336) | (68,537,145) | ||||
Accumulated other comprehensive (loss) | (127,048) | (143,814) | ||||
Stockholders' equity attributable to Parent | 5,243,259 | 2,313,958 | ||||
Stockholders' equity attributable to non-controlling interests | 747,477 | 1,140,666 | ||||
Total Stockholders' Equity | 5,990,736 | 3,454,624 | ||||
Total Liabilities and Stockholders' Equity | $ | 56,046,722 | $ | 56,686,425 | ||
BioHiTech Global, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||||
Nine Months Ended | ||||||
September 30, | ||||||
2021 | 2020 | |||||
Cash flows from operating activities: | ||||||
Net loss | $ | (7,180,291) | $ | (11,719,697) | ||
Adjustments to reconcile net loss to net cash used in operations: | ||||||
Depreciation and amortization | 1,508,284 | 1,747,109 | ||||
Impairment expense | — | 917,420 | ||||
Amortization of operating lease right of use assets | 59,179 | 72,402 | ||||
Provision for bad debts | 45,000 | 126,119 | ||||
Share based employee and vendor compensation | 369,828 | 1,835,750 | ||||
Interest resulting from amortization of financing costs and discounts | 330,916 | 419,715 | ||||
Loss from unconsolidated entity | 43,731 | — | ||||
(Gain) on sale of fixed assets | (8,957) | — | ||||
PPP Loan Forgiveness | (421,300) | — | ||||
Changes in operating assets and liabilities | (924,430) | (909,507) | ||||
Net cash used in operating activities | (6,178,040) | (7,510,689) | ||||
Cash flow used in investing activities: | ||||||
Purchases of facility, equipment, fixtures and vehicles | (252,929) | (207,173) | ||||
Proceeds from sale of vehicle | 8,957 | — | ||||
Refund of deposit | — | 5,000 | ||||
MBT facility development costs incurred | (29,513) | (62,949) | ||||
Net cash used in investing activities | (273,485) | (265,122) | ||||
Cash flows from financing activities: | ||||||
Proceeds from the sales of common stock | 7,548,502 | 8,437,480 | ||||
Proceeds from the sale of Series F convertible preferred stock units | — | 1,560,450 | ||||
Proceeds from Payroll Protection Program Loan | — | 421,300 | ||||
Repayment of Senior secured note | (1,000,000) | — | ||||
Repayments of long-term debt | (3,265) | (3,544) | ||||
Related party advances, net | — | 725,000 | ||||
Net cash provided by financing activities | 6,545,237 | 11,140,686 | ||||
Effect of exchange rate on cash (restricted and unrestricted) | (92) | (18,129) | ||||
Net change in cash (restricted and unrestricted) | 93,620 | 3,346,746 | ||||
Cash - beginning of period (restricted and unrestricted) | 6,896,495 | 5,536,952 | ||||
Cash - end of period (restricted and unrestricted) | $ | 6,990,115 | $ | 8,883,698 | ||
Supplementary cash flow information (cash paid during the periods): | ||||||
Interest | $ | 2,892,850 | $ | 1,596,332 | ||
Income taxes | — | — | ||||
Supplementary Disclosure of Non-Cash Investing and Financing Activities: | ||||||
Transfer of inventory to leased equipment | $ | 54,000 | $ | 84,501 | ||
Acquisition of right of use leased asset and creation of lease liability | — | 412,647 | ||||
Accrual of Series A preferred stock dividends | 35,543 | 52,654 | ||||
Payment of Series A preferred stock dividends in common stock | 79,181 | — | ||||
Conversion of preferred stock into common | — | 239,566 | ||||
Payment of preferred stock dividends in common stock | 390,460 | 21,732 | ||||
Issuance of subsidiary membership interest in exchange for liabilities due non-controlling interest entity | 1,918,947 | — | ||||
Exchange of subsidiary non-controlling interest in exchange for liabilities owed Company by non-controlling interest entity | 333,135 | — | ||||
Reconciliation of Cash and Restricted Cash: | ||||||
Cash | $ | 622,088 | $ | 4,950,112 | ||
Restricted cash (current) | 3,764,521 | 1,287,138 | ||||
Restricted cash (non-current) | 2,603,506 | 2,646,448 | ||||
Total cash and restricted cash at the end of the period | $ | 6,990,115 | $ | 8,883,698 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohitech-global-reports-record-results-with-third-quarter-revenue-up-over-500-from-year-ago-period-301428578.html
SOURCE BioHiTech Global, Inc.
FAQ
What were BioHiTech Global's Q3 2021 revenue figures?
How did BioHiTech Global's operating loss change in Q3 2021?
What is the significance of Carnival Cruise Lines for BioHiTech Global?
What are the gross margins reported by BioHiTech Global for Q3 2021?
What was BioHiTech Global's net loss for Q3 2021?
